SCHEMBL7967035

SCHEMBL7967035

CCC1(CC)C(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
ALOX12 P18054 2/20 0.48
RECQL P46063 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
CASP1 P29466 1/20 0.48
CA7 P43166 1/20 0.48
BACE1 P56817 1/20 0.48
CA9 Q16790 1/20 0.48
EHMT2 Q96KQ7 1/20 0.48
CYP2D6 P10635 1/20 0.47
ELANE P08246 6/20 0.47
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KMT2A Q03164 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9010137 0.87 ELANE (0.42) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL2632159 0.78 ALDH1A1 (0.46) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL9576014 0.76 MAPT (0.45) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL11842335 0.76 CYP2D6 (0.53) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL6814212 0.76 ALDH1A1 (0.44) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL1064500 0.76 ELANE (0.37) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL10623075 0.76 MMP2 (0.50) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL318349 0.75 MEN1 (0.40) ALDH1A1RECQLL3MBTL1CYP2D6ELANE
SCHEMBL14592445 0.73 MAPT (0.66) ALDH1A1ALOX12RECQLL3MBTL1CA1
SCHEMBL31296444 0.73 ALDH1A1 (0.41) ALDH1A1ALOX12RECQLL3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757407-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2017-09-12 US disclosed
US-20130053553-A1 HETEROCYCLIC COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-02-28 US disclosed
US-6180267-B1 Organic electroluminescent device containing a 1,3-dibenzylideneindane compound NEC CORPORATION (JP) 2001-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053553-A1 HETEROCYCLIC COMPOUNDS CYP2C8, UGT1A8, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALDH1A1 674/4885ALOX12 2134/4885RECQL 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.